The U.S. Centers for Disease Control (CDC) has recently disclosed an early warning signal of stroke for those aged 65 and older following the administration of the omicron-specific bivalent booster dose.
The spike in cases comes after a safety signal was identified by the CDC’s Vaccine Safety Datalink (VSD) surveillance system.
“Rapid-response investigation of the signal in the VSD raised a question of whether people 65 and older who have received the Pfizer-BioNTech COVID-19 Vaccine, Bivalent were more likely to have an ischemic stroke in the 21 days following vaccination compared with days 22-42 following vaccination,” the CDC said in a statement on its website. They will continue to analyze data and findings will be discussed at the end of this month.
Ischemic strokes occur when an artery that supplies blood to the brain becomes blocked. The blockage hinders blood flow and oxygen to the brain and if circulation is not restored quickly, brain damage can be permanent.
Through additional analysis of other systems, the CDC determined that no other safety signals have validated the risk. Neither Pfizer nor Moderna’s study, the Veteran Affairs database, the Vaccine Adverse Events Reporting System (VAERS), nor Pfizer’s global safety database have flagged this incidence.
For this reason, the CDC continues to recommend that everyone aged six months of age and older stay up to date with COVID-19 vaccination, including individuals eligible to receive the bivalent booster.
Yet they continue to ignore real-world evidence that the injections are causing harm.
An independent VAERS data interpretation website has continued to find that death reports spike in the days following the COVID-19 injection. The preliminary data shows that this is exponentially more than what has been reported in the decades prior to the rollout of this novel mRNA injection.
Other independent systemic reviews revealed that Pfizer’s own trial data shows an increase in harm, including death, compared to that of the placebo group. Due to the small sample study sizes, as well as the preliminary unblinding of study participants and skewed data interpretation, the manufacturer's own data missed or buried safety signals.
Meanwhile, real-world data dissected by independent review flagged alarming safety signals very early in the injection rollout – primarily the now openly acknowledged risk of myocarditis in young males post-COVID-19 injection.
How many other safety signals will develop as the real-time rollout continues?